Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol NFYB contributors: mct - updated : 18-03-2015
HGNC name nuclear transcription factor Y, beta
HGNC id 7805
EXPRESSION
Type widely
constitutive of
   expressed in (based on citations)
organ(s)
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
a N terminal A domain,a highly conserved central B domain involved in DNA binding,a C terminal C domain rich in glutamine and acidic residues involved in protein-protein interactions
HOMOLOGY
intraspecies homolog to H2B
Homologene
FAMILY cbf-a subfamily
CATEGORY transcription factor
SUBCELLULAR LOCALIZATION     intracellular
intracellular,nucleus
basic FUNCTION
  • essential for expression of the proapoptotic BCL2L11 gene in sympathetic neurons
    • CELLULAR PROCESS nucleotide, transcription
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component forming a trimeric complex with NFYB and NFYC
    INTERACTION
    DNA binding to the CCAAT and the inverted CCAT-box,Y-box (ATGG) motifs in a variety of promoters
    RNA
    small molecule
    protein
  • interacting with SARS2 (NFYA, NFYB, NFYC influences directionality of transcription from the bidirectional MRPS12/SARS2 promoter)
  • NFYA, NFYB, NFYC, cooperates with FOXO3 to recruit EP300 to the BCL2L11 promoter to form a stable multi-protein/DNA complex that activates BCL2L11 transcription after survival factor withdrawal
  • NFYA, NFYB, NFYC can act as a transcriptional activator of ABCB4
  • NFYA, NFYB, NFYC and YY1 are important for the basal transcription of PCYT2 and NFY is involved in the inhibitory effects of 25-HC on PCYT2 transcription
    • cell & other
    REGULATION
    activated by ATF6
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional       loss of function
    impaired cells from exiting G2/M, but did not interfere with S-phase progression (
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    ANIMAL & CELL MODELS